Drug Type Small molecule drug |
Synonyms AK 106 001616, AK-106, AK106-001616 |
Target |
Mechanism cPLA2α inhibitors(Cytosolic phospholipase A2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H25N3O3 |
InChIKeyULNYPYSSPODXCS-UHFFFAOYSA-N |
CAS Registry590416-75-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | CZ | 01 May 2009 | |
Rheumatoid Arthritis | Phase 2 | DE | 01 May 2009 | |
Rheumatoid Arthritis | Phase 2 | HU | 01 May 2009 | |
Rheumatoid Arthritis | Phase 2 | LT | 01 May 2009 | |
Rheumatoid Arthritis | Phase 2 | RO | 01 May 2009 | |
Rheumatoid Arthritis | Phase 2 | GB | 01 May 2009 |
Phase 2 | 253 | AK106-001616 100 mg | wmubxlnuji(krptsegtfo) = lnkobszkyf tadgsdmtcs (alytlgctrs ) | Positive | 12 Jun 2013 | ||
AK106-001616 600 mg | wmubxlnuji(krptsegtfo) = kttwsagebi tadgsdmtcs (alytlgctrs ) |